chatGPT(6AstraMaxPaid):
Summary
In the Future Biotech Expo Q&A, Dr David Barzilai argues that longevity medicine should be judged by outcomes that matter to patients, not by a change in a biological-age score or a promising mechanism.
He sees genuine progress in drugs with demonstrated clinical benefits, faster AI-assisted drug discovery, and the first human trial of partial epigenetic reprogramming. But he expects the largest near-term healthspan gains to come from wider, earlier use of established measures: managing cardiovascular risk, improving fitness and sleep, screening appropriately, and addressing hearing loss.
He is cautious about biological-age tests: a result may be interesting without being reliable enough, or sufficiently linked to health outcomes, to guide treatment. He makes the same distinction in Alzheimer’s disease. Blood tests are making pathology easier to identify, while available disease-modifying treatments offer modest measured benefit alongside meaningful risks. His proposed route for longevity companies is to test a therapy in a defined disease, specify in advance what result would change a clinical or regulatory decision, and build evidence that patients benefit.
What is distinctive
This is an interview, not a report of new research. Its strongest contribution is a practical test for claims: What result would prove this wrong, and would using the product leave a person better off?
Two points are particularly useful. Barzilai separates a biomarker’s ability to predict risk from evidence that changing that biomarker improves outcomes. He also treats validated aging endpoints as shared research infrastructure that individual companies have little incentive to fund alone. That makes the discussion of trial design, regulators, clinicians and public funding more concrete than a typical longevity overview. ARPA-H’s PROSPR programme is a real example of investment in that infrastructure, though its proposed measures and trials still need to prove their value. (ARPA-H)
Critique
- The evidence hierarchy is sound, but some examples carry less weight than the framing suggests. SELECT showed that semaglutide reduced major cardiovascular events in a defined population with established cardiovascular disease and overweight or obesity. It did not establish that the drug slows aging itself. Barzilai generally preserves that distinction, but placing it among the leading developments in longevity could blur it for readers. (New England Journal of Medicine)
- “No therapy has been shown to slow human aging” is a defensible clinical standard, but it depends on what counts as proof. His intended standard is a human trial with meaningful outcomes that cannot be explained solely as treatment of one disease. The absence of such a trial is not evidence that every proposed aging intervention is ineffective.
- The Alzheimer’s section could distinguish detection from useful early intervention more sharply. A blood test can help assess pathology in a person being evaluated for cognitive impairment; that does not establish a benefit from screening people without symptoms. Current Alzheimer’s Association criteria do not support testing asymptomatic people for clinical care outside research. (Alzheimer’s Association)
- It gives little attention to how to test mechanisms across multiple tissues or diseases. That is especially relevant to hypotheses about mitochondrial function, acetyl-CoA and transcription: a disease-specific trial may establish a useful treatment while leaving its proposed general effect on aging unresolved.
Overall, it is a strong guide to evaluating longevity claims and designing useful trials, rather than a survey of aging mechanisms. Its most valuable insistence is that an exciting measurement or biological effect still needs a demonstrated link to better health.